egen-001
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT00137865)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- egen-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01489371 | Phase 1 | Jul 1, 2012 | Gynecologic Oncology Group, National Cancer Institute (NCI) |
| NCT01300858 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2011 | EGEN, Inc. |
| NCT00473954 | Phase 1 | Apr 1, 2007 | EGEN, Inc., University of Alabama, Birmingham |
| NCT00137865 | Phase 1 | Aug 1, 2005 | EGEN, Inc., University of Alabama, Birmingham |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EGEN, Inc. | For profit | 3 | 3 | 2 | 2005 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 0 | 1 | 2005 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2012 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2012 |
4 organizations
Page 1 / 1